Emerging Drug Developer: Synosia Therapeutics

Synosia Therapeutics

Back in 2005, Synosia Therapeutics was little more than a gleam in a venture capitalist's eye.

Bradley Bolzon, an experienced biotech player and an accomplished dealmaker with Roche, had gone on to become a partner at Versant Ventures. Several years ago he reached out to an old colleague from Roche days, Ian Massey, a 30-year biotech veteran and the senior vice president of research and preclinical development for Roche Palo Alto. An A1 round of $2.5 million to prime the pump was swiftly followed by an A2 round of $30 million. And today, Synosia has a portfolio of six clinical-stage therapeutics, four of which are either already in a mid-stage trial or ready to begin one. Article

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.